Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1991-07

AUTHORS

W. P. Steward, J. Verweij, R. Somers, G. Blackledge, M. Clavel, A. T. Van Oosterom, B. Greifenberg, J. Soedirman, D. Thomas, M. Van Glabbeke, K. Kelly

ABSTRACT

Doxorubicin and ifosfamide are the two most active agents used in the treatment of advanced inoperable soft-tissue sarcoma, but their use in combination produces dose-limiting myelosuppression. To explore the feasibility of combining optimal doses of both drugs, doxorubicin (75 mg/m2) and ifosfamide (5 g/m2) were given every 3 weeks with recombinant human granulocyte/macrophage-colony-stimulating factor (rhGM-CSF; 250 micrograms m-2 day-1) by subcutaneous injection for up to 14 days after each course. A total of 52 patients with progressive metastatic soft-tissue sarcoma were entered, none having received prior chemotherapy. One patient was ineligible and received no treatment after registration. Preliminary analysis of six cycles of chemotherapy revealed that the full protocol dose intensity had been administered to the majority of patients. Although the median leucocyte and neutrophil counts did not fall with subsequent courses of chemotherapy, the duration of neutropenia increased with each course delivered. Cumulative thrombocytopenia was a major dose-limiting toxicity and was the main reason for any dose modifications that occurred. Although 26 patients experienced infections after one or more courses of treatment, in only 7 was admission required for parenteral antibiotics. One patient died as a result of septicaemia after the first cycle of treatment. To date, there have been 22 responses (43%) with 8% complete remissions. It appears that the administration of rhGM-CSF allows this high-dose regime of chemotherapy to be given safely and the early encouraging response rate adds support to the concept that increasing the dose of doxorubicin improves the outlook for patients with advanced soft-tissue sarcomas. More... »

PAGES

s193-s197

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf01613226

DOI

http://dx.doi.org/10.1007/bf01613226

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1009470527

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1795008


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Granulocyte-Macrophage Colony-Stimulating Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ifosfamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Remission Induction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sarcoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Soft Tissue Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Beatson Oncology Centre, Western Infirmary, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Steward", 
        "givenName": "W. P.", 
        "id": "sg:person.01160603626.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160603626.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Erasmus University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5645.2", 
          "name": [
            "Rotterdam Cancer Institute, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Verweij", 
        "givenName": "J.", 
        "id": "sg:person.01236641403.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236641403.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Antoni van Leeuwenhoekhuis, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Somers", 
        "givenName": "R.", 
        "id": "sg:person.01046136363.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046136363.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen Elizabeth Hospital Birmingham", 
          "id": "https://www.grid.ac/institutes/grid.415490.d", 
          "name": [
            "Queen Elizabeth Hospital, Birmingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blackledge", 
        "givenName": "G.", 
        "id": "sg:person.010230073064.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010230073064.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Centre L\u00e9on Berard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clavel", 
        "givenName": "M.", 
        "id": "sg:person.0740521463.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740521463.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University Hospital, Antwerp, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Oosterom", 
        "givenName": "A. T.", 
        "id": "sg:person.0653245357.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653245357.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Behringwerke (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420054.7", 
          "name": [
            "Behringwerke, Marburg, Federal Republic of Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Greifenberg", 
        "givenName": "B.", 
        "id": "sg:person.01070337636.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070337636.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Behringwerke (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420054.7", 
          "name": [
            "Behringwerke, Marburg, Federal Republic of Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Soedirman", 
        "givenName": "J.", 
        "id": "sg:person.01207050256.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207050256.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "European Organisation for Research and Treatment of Cancer", 
          "id": "https://www.grid.ac/institutes/grid.418936.1", 
          "name": [
            "EORTC Data Centre, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thomas", 
        "givenName": "D.", 
        "id": "sg:person.01024160143.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024160143.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "European Organisation for Research and Treatment of Cancer", 
          "id": "https://www.grid.ac/institutes/grid.418936.1", 
          "name": [
            "EORTC Data Centre, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Glabbeke", 
        "givenName": "M.", 
        "id": "sg:person.077417175.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.077417175.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen Elizabeth Hospital Birmingham", 
          "id": "https://www.grid.ac/institutes/grid.415490.d", 
          "name": [
            "Queen Elizabeth Hospital, Birmingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kelly", 
        "givenName": "K.", 
        "id": "sg:person.01157502625.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157502625.10"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1002/1097-0142(19840501)53:9<1825::aid-cncr2820530904>3.0.co;2-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005906256"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm198809083191001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008155713"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0277-5379(87)90075-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008471618"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0167-8140(86)80049-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014621685"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1990.167", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015645050", 
          "https://doi.org/10.1038/bjc.1990.167"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1990.167", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015645050", 
          "https://doi.org/10.1038/bjc.1990.167"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00254247", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017390161", 
          "https://doi.org/10.1007/bf00254247"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00254247", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017390161", 
          "https://doi.org/10.1007/bf00254247"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1989.28", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022624090", 
          "https://doi.org/10.1038/bjc.1989.28"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1989.28", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022624090", 
          "https://doi.org/10.1038/bjc.1989.28"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0305-7372(77)80006-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034055014"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0277-5379(90)90075-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035067083"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(197705)39:5<1940::aid-cncr2820390505>3.0.co;2-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041180363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1987.295", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042150907", 
          "https://doi.org/10.1038/bjc.1987.295"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1989.234", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046548152", 
          "https://doi.org/10.1038/bjc.1989.234"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1989.234", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046548152", 
          "https://doi.org/10.1038/bjc.1989.234"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/81.19.1510-a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059815381"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-110-5-357", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073693792"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078438631", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079412441", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1986.4.8.1157", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079801510"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1986.4.8.1162", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079801511"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082319980", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1991-07", 
    "datePublishedReg": "1991-07-01", 
    "description": "Doxorubicin and ifosfamide are the two most active agents used in the treatment of advanced inoperable soft-tissue sarcoma, but their use in combination produces dose-limiting myelosuppression. To explore the feasibility of combining optimal doses of both drugs, doxorubicin (75 mg/m2) and ifosfamide (5 g/m2) were given every 3 weeks with recombinant human granulocyte/macrophage-colony-stimulating factor (rhGM-CSF; 250 micrograms m-2 day-1) by subcutaneous injection for up to 14 days after each course. A total of 52 patients with progressive metastatic soft-tissue sarcoma were entered, none having received prior chemotherapy. One patient was ineligible and received no treatment after registration. Preliminary analysis of six cycles of chemotherapy revealed that the full protocol dose intensity had been administered to the majority of patients. Although the median leucocyte and neutrophil counts did not fall with subsequent courses of chemotherapy, the duration of neutropenia increased with each course delivered. Cumulative thrombocytopenia was a major dose-limiting toxicity and was the main reason for any dose modifications that occurred. Although 26 patients experienced infections after one or more courses of treatment, in only 7 was admission required for parenteral antibiotics. One patient died as a result of septicaemia after the first cycle of treatment. To date, there have been 22 responses (43%) with 8% complete remissions. It appears that the administration of rhGM-CSF allows this high-dose regime of chemotherapy to be given safely and the early encouraging response rate adds support to the concept that increasing the dose of doxorubicin improves the outlook for patients with advanced soft-tissue sarcomas.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf01613226", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1313647", 
        "issn": [
          "0171-5216", 
          "1432-1335"
        ], 
        "name": "Journal of Cancer Research and Clinical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "117"
      }
    ], 
    "name": "Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group", 
    "pagination": "s193-s197", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2d1cf38cc42e8eeb0feafc04f787909e6b2652d9b7e38ac87a9fb811ad52c477"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1795008"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7902060"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf01613226"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1009470527"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf01613226", 
      "https://app.dimensions.ai/details/publication/pub.1009470527"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:51", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8681_00000486.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF01613226"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf01613226'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf01613226'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf01613226'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf01613226'


 

This table displays all metadata directly associated to this object as RDF triples.

276 TRIPLES      21 PREDICATES      63 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf01613226 schema:about N00b2d72f4cf84a45a3779cd246d48ae9
2 N12b5d6e8035b4b23a3e3a9da42c2ae19
3 N2262cca42fea426a8b09dcd5710a6565
4 N25e77844fc6c4a0891c1e7034a29d24f
5 N3b322a929d57489c9589551218fca3ad
6 N4881ebedffda420898679fe4c5ae821b
7 N5a51e6d9eea74e4280e8033e015e89a9
8 N8aebb42035a84532914f97bb5e9e8bde
9 N8c52867419a44c15a07618961cc0c2bb
10 N9f24455b3dbb484aa6bb0d994632af8f
11 Nad240a6ba08245a983e150eb4a1e4769
12 Nbe4bfaeb390341699aae64982917012e
13 Nc6201246ebcd49a0bda7afaee99c328b
14 Nd6884c75ba0f4b86abbdbf48550efa9c
15 Ndedccd7c685a45e6a89bc160ef4178d7
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N267395c13a3d40f5be36c1b7a0929625
19 schema:citation sg:pub.10.1007/bf00254247
20 sg:pub.10.1038/bjc.1987.295
21 sg:pub.10.1038/bjc.1989.234
22 sg:pub.10.1038/bjc.1989.28
23 sg:pub.10.1038/bjc.1990.167
24 https://app.dimensions.ai/details/publication/pub.1078438631
25 https://app.dimensions.ai/details/publication/pub.1079412441
26 https://app.dimensions.ai/details/publication/pub.1082319980
27 https://doi.org/10.1002/1097-0142(197705)39:5<1940::aid-cncr2820390505>3.0.co;2-0
28 https://doi.org/10.1002/1097-0142(19840501)53:9<1825::aid-cncr2820530904>3.0.co;2-z
29 https://doi.org/10.1016/0277-5379(87)90075-7
30 https://doi.org/10.1016/0277-5379(90)90075-5
31 https://doi.org/10.1016/s0167-8140(86)80049-4
32 https://doi.org/10.1016/s0305-7372(77)80006-6
33 https://doi.org/10.1056/nejm198809083191001
34 https://doi.org/10.1093/jnci/81.19.1510-a
35 https://doi.org/10.1200/jco.1986.4.8.1157
36 https://doi.org/10.1200/jco.1986.4.8.1162
37 https://doi.org/10.7326/0003-4819-110-5-357
38 schema:datePublished 1991-07
39 schema:datePublishedReg 1991-07-01
40 schema:description Doxorubicin and ifosfamide are the two most active agents used in the treatment of advanced inoperable soft-tissue sarcoma, but their use in combination produces dose-limiting myelosuppression. To explore the feasibility of combining optimal doses of both drugs, doxorubicin (75 mg/m2) and ifosfamide (5 g/m2) were given every 3 weeks with recombinant human granulocyte/macrophage-colony-stimulating factor (rhGM-CSF; 250 micrograms m-2 day-1) by subcutaneous injection for up to 14 days after each course. A total of 52 patients with progressive metastatic soft-tissue sarcoma were entered, none having received prior chemotherapy. One patient was ineligible and received no treatment after registration. Preliminary analysis of six cycles of chemotherapy revealed that the full protocol dose intensity had been administered to the majority of patients. Although the median leucocyte and neutrophil counts did not fall with subsequent courses of chemotherapy, the duration of neutropenia increased with each course delivered. Cumulative thrombocytopenia was a major dose-limiting toxicity and was the main reason for any dose modifications that occurred. Although 26 patients experienced infections after one or more courses of treatment, in only 7 was admission required for parenteral antibiotics. One patient died as a result of septicaemia after the first cycle of treatment. To date, there have been 22 responses (43%) with 8% complete remissions. It appears that the administration of rhGM-CSF allows this high-dose regime of chemotherapy to be given safely and the early encouraging response rate adds support to the concept that increasing the dose of doxorubicin improves the outlook for patients with advanced soft-tissue sarcomas.
41 schema:genre research_article
42 schema:inLanguage en
43 schema:isAccessibleForFree false
44 schema:isPartOf N94a53e97f23b41ec8e59f168b433a8cd
45 N98f5ab904f584ac496e93d1fdda92888
46 sg:journal.1313647
47 schema:name Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group
48 schema:pagination s193-s197
49 schema:productId N0821410c0ecb4cc396672fcd7072e0f4
50 N0a19eeff8e224f48baf62ad64668d915
51 N4403c1aeae174b318e92629e4f592664
52 N5a7fe507a9b24593b3f01c3dd34f6d7e
53 N85ec5dcdb3fe4aa9b7db4c07a5a77f2d
54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009470527
55 https://doi.org/10.1007/bf01613226
56 schema:sdDatePublished 2019-04-10T19:51
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher N7e8a7cf70dba43f0bfc641934b3999d5
59 schema:url http://link.springer.com/10.1007/BF01613226
60 sgo:license sg:explorer/license/
61 sgo:sdDataset articles
62 rdf:type schema:ScholarlyArticle
63 N00b2d72f4cf84a45a3779cd246d48ae9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Sarcoma
65 rdf:type schema:DefinedTerm
66 N05c3d2c0586b40aab03b41d40054e783 schema:name Beatson Oncology Centre, Western Infirmary, Glasgow, UK
67 rdf:type schema:Organization
68 N0821410c0ecb4cc396672fcd7072e0f4 schema:name dimensions_id
69 schema:value pub.1009470527
70 rdf:type schema:PropertyValue
71 N0a19eeff8e224f48baf62ad64668d915 schema:name pubmed_id
72 schema:value 1795008
73 rdf:type schema:PropertyValue
74 N12b5d6e8035b4b23a3e3a9da42c2ae19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Female
76 rdf:type schema:DefinedTerm
77 N2262cca42fea426a8b09dcd5710a6565 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Recombinant Proteins
79 rdf:type schema:DefinedTerm
80 N25e77844fc6c4a0891c1e7034a29d24f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Aged
82 rdf:type schema:DefinedTerm
83 N267395c13a3d40f5be36c1b7a0929625 rdf:first sg:person.01160603626.09
84 rdf:rest N5ec155b4e24b466788f234b1049d0f1a
85 N3b322a929d57489c9589551218fca3ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Male
87 rdf:type schema:DefinedTerm
88 N3f75c877743846e8904f206a292afd94 schema:name University Hospital, Antwerp, Belgium
89 rdf:type schema:Organization
90 N4403c1aeae174b318e92629e4f592664 schema:name nlm_unique_id
91 schema:value 7902060
92 rdf:type schema:PropertyValue
93 N46e4f72dcb86469f9c8ded7e1f5e6ae0 rdf:first sg:person.0740521463.56
94 rdf:rest N9c0b3b74b18040e7951191dcf31caabc
95 N4881ebedffda420898679fe4c5ae821b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Adult
97 rdf:type schema:DefinedTerm
98 N5a51e6d9eea74e4280e8033e015e89a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Doxorubicin
100 rdf:type schema:DefinedTerm
101 N5a7fe507a9b24593b3f01c3dd34f6d7e schema:name readcube_id
102 schema:value 2d1cf38cc42e8eeb0feafc04f787909e6b2652d9b7e38ac87a9fb811ad52c477
103 rdf:type schema:PropertyValue
104 N5ec155b4e24b466788f234b1049d0f1a rdf:first sg:person.01236641403.86
105 rdf:rest Nb8671032f0e146378dd39b98d65e6528
106 N7e8a7cf70dba43f0bfc641934b3999d5 schema:name Springer Nature - SN SciGraph project
107 rdf:type schema:Organization
108 N85ec5dcdb3fe4aa9b7db4c07a5a77f2d schema:name doi
109 schema:value 10.1007/bf01613226
110 rdf:type schema:PropertyValue
111 N8aebb42035a84532914f97bb5e9e8bde schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Remission Induction
113 rdf:type schema:DefinedTerm
114 N8c52867419a44c15a07618961cc0c2bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Soft Tissue Neoplasms
116 rdf:type schema:DefinedTerm
117 N94a53e97f23b41ec8e59f168b433a8cd schema:issueNumber Suppl 4
118 rdf:type schema:PublicationIssue
119 N98f5ab904f584ac496e93d1fdda92888 schema:volumeNumber 117
120 rdf:type schema:PublicationVolume
121 N9c0b3b74b18040e7951191dcf31caabc rdf:first sg:person.0653245357.14
122 rdf:rest Nd0a89d0c6dab44f58dbd4363fa3aa1e0
123 N9cd16d0bd3e441a8bae7cf7511beb269 rdf:first sg:person.01024160143.84
124 rdf:rest Nd3e5e14585fb4ffaa502bb7b21ad15ff
125 N9f24455b3dbb484aa6bb0d994632af8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Drug Evaluation
127 rdf:type schema:DefinedTerm
128 Nac45c0053ca24f4382cd029726a05aef rdf:first sg:person.010230073064.41
129 rdf:rest N46e4f72dcb86469f9c8ded7e1f5e6ae0
130 Nad240a6ba08245a983e150eb4a1e4769 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Antineoplastic Combined Chemotherapy Protocols
132 rdf:type schema:DefinedTerm
133 Nb8671032f0e146378dd39b98d65e6528 rdf:first sg:person.01046136363.16
134 rdf:rest Nac45c0053ca24f4382cd029726a05aef
135 Nbe4bfaeb390341699aae64982917012e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Granulocyte-Macrophage Colony-Stimulating Factor
137 rdf:type schema:DefinedTerm
138 Nc6201246ebcd49a0bda7afaee99c328b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Ifosfamide
140 rdf:type schema:DefinedTerm
141 Nc7efc7b8729a4cff974f712bcbeef749 schema:name Antoni van Leeuwenhoekhuis, Amsterdam, The Netherlands
142 rdf:type schema:Organization
143 Nd0a89d0c6dab44f58dbd4363fa3aa1e0 rdf:first sg:person.01070337636.18
144 rdf:rest Nf2c257d7d52a41178d0f78105f335877
145 Nd3e5e14585fb4ffaa502bb7b21ad15ff rdf:first sg:person.077417175.36
146 rdf:rest Nf1ade6c5d49c4cfeb0ee2953481911fd
147 Nd6884c75ba0f4b86abbdbf48550efa9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Middle Aged
149 rdf:type schema:DefinedTerm
150 Ndedccd7c685a45e6a89bc160ef4178d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Humans
152 rdf:type schema:DefinedTerm
153 Nf1ade6c5d49c4cfeb0ee2953481911fd rdf:first sg:person.01157502625.10
154 rdf:rest rdf:nil
155 Nf2c257d7d52a41178d0f78105f335877 rdf:first sg:person.01207050256.08
156 rdf:rest N9cd16d0bd3e441a8bae7cf7511beb269
157 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
158 schema:name Medical and Health Sciences
159 rdf:type schema:DefinedTerm
160 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
161 schema:name Oncology and Carcinogenesis
162 rdf:type schema:DefinedTerm
163 sg:journal.1313647 schema:issn 0171-5216
164 1432-1335
165 schema:name Journal of Cancer Research and Clinical Oncology
166 rdf:type schema:Periodical
167 sg:person.010230073064.41 schema:affiliation https://www.grid.ac/institutes/grid.415490.d
168 schema:familyName Blackledge
169 schema:givenName G.
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010230073064.41
171 rdf:type schema:Person
172 sg:person.01024160143.84 schema:affiliation https://www.grid.ac/institutes/grid.418936.1
173 schema:familyName Thomas
174 schema:givenName D.
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024160143.84
176 rdf:type schema:Person
177 sg:person.01046136363.16 schema:affiliation Nc7efc7b8729a4cff974f712bcbeef749
178 schema:familyName Somers
179 schema:givenName R.
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046136363.16
181 rdf:type schema:Person
182 sg:person.01070337636.18 schema:affiliation https://www.grid.ac/institutes/grid.420054.7
183 schema:familyName Greifenberg
184 schema:givenName B.
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070337636.18
186 rdf:type schema:Person
187 sg:person.01157502625.10 schema:affiliation https://www.grid.ac/institutes/grid.415490.d
188 schema:familyName Kelly
189 schema:givenName K.
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157502625.10
191 rdf:type schema:Person
192 sg:person.01160603626.09 schema:affiliation N05c3d2c0586b40aab03b41d40054e783
193 schema:familyName Steward
194 schema:givenName W. P.
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160603626.09
196 rdf:type schema:Person
197 sg:person.01207050256.08 schema:affiliation https://www.grid.ac/institutes/grid.420054.7
198 schema:familyName Soedirman
199 schema:givenName J.
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207050256.08
201 rdf:type schema:Person
202 sg:person.01236641403.86 schema:affiliation https://www.grid.ac/institutes/grid.5645.2
203 schema:familyName Verweij
204 schema:givenName J.
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236641403.86
206 rdf:type schema:Person
207 sg:person.0653245357.14 schema:affiliation N3f75c877743846e8904f206a292afd94
208 schema:familyName Van Oosterom
209 schema:givenName A. T.
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653245357.14
211 rdf:type schema:Person
212 sg:person.0740521463.56 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
213 schema:familyName Clavel
214 schema:givenName M.
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740521463.56
216 rdf:type schema:Person
217 sg:person.077417175.36 schema:affiliation https://www.grid.ac/institutes/grid.418936.1
218 schema:familyName Van Glabbeke
219 schema:givenName M.
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.077417175.36
221 rdf:type schema:Person
222 sg:pub.10.1007/bf00254247 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017390161
223 https://doi.org/10.1007/bf00254247
224 rdf:type schema:CreativeWork
225 sg:pub.10.1038/bjc.1987.295 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042150907
226 https://doi.org/10.1038/bjc.1987.295
227 rdf:type schema:CreativeWork
228 sg:pub.10.1038/bjc.1989.234 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046548152
229 https://doi.org/10.1038/bjc.1989.234
230 rdf:type schema:CreativeWork
231 sg:pub.10.1038/bjc.1989.28 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022624090
232 https://doi.org/10.1038/bjc.1989.28
233 rdf:type schema:CreativeWork
234 sg:pub.10.1038/bjc.1990.167 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015645050
235 https://doi.org/10.1038/bjc.1990.167
236 rdf:type schema:CreativeWork
237 https://app.dimensions.ai/details/publication/pub.1078438631 schema:CreativeWork
238 https://app.dimensions.ai/details/publication/pub.1079412441 schema:CreativeWork
239 https://app.dimensions.ai/details/publication/pub.1082319980 schema:CreativeWork
240 https://doi.org/10.1002/1097-0142(197705)39:5<1940::aid-cncr2820390505>3.0.co;2-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041180363
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1002/1097-0142(19840501)53:9<1825::aid-cncr2820530904>3.0.co;2-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1005906256
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1016/0277-5379(87)90075-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008471618
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1016/0277-5379(90)90075-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035067083
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1016/s0167-8140(86)80049-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014621685
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1016/s0305-7372(77)80006-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034055014
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1056/nejm198809083191001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008155713
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1093/jnci/81.19.1510-a schema:sameAs https://app.dimensions.ai/details/publication/pub.1059815381
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1200/jco.1986.4.8.1157 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079801510
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1200/jco.1986.4.8.1162 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079801511
259 rdf:type schema:CreativeWork
260 https://doi.org/10.7326/0003-4819-110-5-357 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073693792
261 rdf:type schema:CreativeWork
262 https://www.grid.ac/institutes/grid.415490.d schema:alternateName Queen Elizabeth Hospital Birmingham
263 schema:name Queen Elizabeth Hospital, Birmingham, UK
264 rdf:type schema:Organization
265 https://www.grid.ac/institutes/grid.418116.b schema:alternateName Centre Léon Bérard
266 schema:name Centre Léon Berard, Lyon, France
267 rdf:type schema:Organization
268 https://www.grid.ac/institutes/grid.418936.1 schema:alternateName European Organisation for Research and Treatment of Cancer
269 schema:name EORTC Data Centre, Brussels, Belgium
270 rdf:type schema:Organization
271 https://www.grid.ac/institutes/grid.420054.7 schema:alternateName Behringwerke (Germany)
272 schema:name Behringwerke, Marburg, Federal Republic of Germany
273 rdf:type schema:Organization
274 https://www.grid.ac/institutes/grid.5645.2 schema:alternateName Erasmus University Medical Center
275 schema:name Rotterdam Cancer Institute, The Netherlands
276 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...